Margaret E Bates, MD
Obstetrics/Gynecology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 49 years
- University of Southern California Keck School of Medicine, 1977
Offices
3 locations · Pih Health Physicians · 616 clinicians in this group
Hospitals listed: USC Verdugo Hills Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bates’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G50676 · Current
Licensed to practise in California · since 1983 · expires 2028-08-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- USC Verdugo Hills HospitalGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of Southern California, which runs 4 hospitalsPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.19, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.5 to 1) · 396 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for USC Verdugo Hills Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 4 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.19 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.5 to 1) · 396 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.94) · 627 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.51 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.68 (110.02 to 233.35) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 73 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.4 · 246 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 70 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,469 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,522 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 3,622 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.54 (1.21 to 5.88) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.45 (0 to 3.06) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.03 to 4.29) · 511 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.7 (2.76 to 20.64) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.55 (0.5 to 8.6) · 189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.2) · 181 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.22 (0 to 1.01) · 2,841 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.263 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.733 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 48 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 273 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 2.6 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 28.2 · 377 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 392 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 90 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.2 (8.5 to 14.8) · 881 cases | No different | Jan 2022 – Dec 2024 |
What patients said (413 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$4,660
Medicare paid this office $4,660 for 72 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,866 | $42 |
| Short return visit | 17 | $974 | $42 |
| Short return visit (20+ min) | 12 | $821 | $68 |
Who their Medicare patients are
72 Original Medicare patients in 2024. Average age 75 · Women 100% · Health risk score 0.76. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 61% · Coronary heart disease 19% · Depression 19% · Diabetes 15% · Cancer 15%.
The office billed $13,524, Medicare allowed $5,728 and paid $4,660; for 95 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 72 | 95 | 75 | 0.76 | $13,524 | $4,660 |
| 2023 | 72 | 129 | 74 | 0.71 | $22,945 | $6,854 |
| 2022 | 79 | 147 | 73 | 0.77 | $21,800 | $9,529 |
| 2021 | 73 | 136 | 73 | 0.66 | $15,275 | $7,612 |
| 2020 | 74 | 130 | 74 | 0.69 | $15,275 | $7,149 |
| 2019 | 109 | 202 | 74 | 0.75 | $22,035 | $9,949 |
| 2018 | 101 | 178 | 73 | 0.94 | $18,840 | $8,490 |
| 2017 | 138 | 213 | 74 | 0.84 | $28,395 | $9,690 |
| 2016 | 153 | 249 | 74 | 0.82 | $37,220 | $11,838 |
| 2015 | 152 | 225 | 73 | 0.89 | $36,865 | $12,111 |
| 2014 | 145 | 292 | 73 | 0.84 | $41,753 | $14,864 |
| 2013 | 93 | 134 | 75 | 0.82 | $20,110 | $6,946 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,186 | $43 |
| Short return visit (20+ min) | 18 | $1,331 | $63 |
| Short return visit | 16 | $1,090 | $47 |
2022: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 47 | $2,299 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 48 | $2,091 | $44 |
| Return visit (30+ min) | 15 | $1,663 | $111 |
| Short return visit (20+ min) | 17 | $1,273 | $71 |
2021: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 52 | $2,571 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 53 | $2,325 | $44 |
| Return visit (30+ min) | 11 | $1,250 | $114 |
| Short return visit (20+ min) | 13 | $974 | $70 |
2020: 3 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,252 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 47 | $2,086 | $44 |
| Short return visit (20+ min) | 18 | $1,073 | $54 |
2019: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 62 | $3,022 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 67 | $2,867 | $43 |
| Short return visit (20+ min) | 37 | $2,316 | $54 |
| Return visit (30+ min) | 13 | $990 | $71 |
2018: 3 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 67 | $3,151 | $47 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 59 | $2,329 | $39 |
| Short return visit (20+ min) | 34 | $1,791 | $47 |
2017: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 78 | $3,069 | $39 |
| Short return visit (20+ min) | 56 | $3,046 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 27 | $1,261 | $47 |
| Short return visit | 15 | $608 | $32 |
2016: 3 services
| Short return visit (20+ min) | 78 | $4,739 | $48 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 87 | $3,488 | $40 |
| Short return visit | 26 | $1,040 | $32 |
2015: 4 services
| Short return visit (20+ min) | 69 | $4,609 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 79 | $3,221 | $41 |
| Return visit (30+ min) | 19 | $1,326 | $66 |
| Short return visit | 15 | $523 | $31 |
2014: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 99 | $4,045 | $41 |
| Short return visit (20+ min) | 59 | $3,984 | $55 |
| Return visit (30+ min) | 19 | $1,853 | $81 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 24 | $1,174 | $49 |
| Short return visit | 15 | $432 | $27 |
2013: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 50 | $2,041 | $41 |
| Short return visit (20+ min) | 22 | $1,361 | $62 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 24 | $1,200 | $50 |
| Short return visit | 12 | $489 | $38 |
Drugs they prescribed that Part D paid
$22,852
Pharmacies billed $22,852 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 148) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
119 generic and 29 brand-name prescriptions · $22,852 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 37 | $3,528 | $95 |
| Estradiol (Twice Weekly) | 11 | $1,707 | $155 |
Year by year
| 2024 | 148 | 51 | 0% (0) | 20% | $22,852 |
| 2023 | 175 | 49 | 0% (0) | None | $26,702 |
| 2022 | 194 | 43 | 0% (0) | None | $28,540 |
| 2021 | 176 | 41 | 0% (0) | 15% | $21,938 |
| 2020 | 181 | 37 | 0% (0) | 31% | $26,202 |
| 2019 | 215 | 45 | 0% (0) | 30% | $28,560 |
| 2018 | 250 | 52 | 0% (0) | 34% | $23,794 |
| 2017 | 225 | 45 | 0% (0) | 36% | $22,392 |
| 2016 | 238 | 51 | 0% (0) | 39% | $22,305 |
| 2015 | 253 | 49 | None | 52% | $24,663 |
| 2014 | 257 | 54 | 0% (0) | 60% | $25,300 |
| 2013 | 252 | 45 | 0% (0) | 66% | $23,279 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estradiol (Twice Weekly) | 17 | $3,173 | $187 |
| Estradiol | 31 | $2,886 | $93 |
| Progesterone | 11 | $172 | $16 |
2022: 4 drugs
| Estradiol (Twice Weekly) | 20 | $2,994 | $150 |
| Progesterone | 23 | $1,761 | $77 |
| Estradiol | 17 | $920 | $54 |
| Lorazepam | 12 | $65 | $5 |
2021: 5 drugs
| Estradiol (Twice Weekly) | 14 | $1,991 | $142 |
| Progesterone | 21 | $1,880 | $90 |
| Dotti | 12 | $829 | $69 |
| Estradiol | 18 | $780 | $43 |
| Lorazepam | 13 | $131 | $10 |
2020: 4 drugs
| Progesterone | 30 | $2,650 | $88 |
| Estradiol (Twice Weekly) | 20 | $2,609 | $130 |
| Estradiol | 16 | $555 | $35 |
| Lorazepam | 14 | $47 | $3 |
2019: 4 drugs
| Premarin | 22 | $7,789 | $354 |
| Estradiol | 62 | $6,887 | $111 |
| Progesterone | 33 | $3,025 | $92 |
| Lorazepam | 14 | $30 | $2 |
2018: 6 drugs
| Estradiol | 84 | $7,838 | $93 |
| Premarin | 24 | $6,393 | $266 |
| Progesterone | 32 | $2,532 | $79 |
| Acyclovir | 11 | $561 | $51 |
| Norethindrone Acetate | 12 | $246 | $21 |
| Lorazepam | 13 | $35 | $3 |
2017: 4 drugs
| Premarin | 24 | $6,423 | $268 |
| Estradiol | 49 | $4,291 | $88 |
| Progesterone | 36 | $2,658 | $74 |
| Norethindrone Acetate | 18 | $422 | $23 |
2016: 6 drugs
| Premarin | 27 | $5,882 | $218 |
| Vagifem | 25 | $5,761 | $230 |
| Estradiol | 48 | $3,576 | $74 |
| Progesterone | 27 | $1,709 | $63 |
| Norethindrone Acetate | 19 | $632 | $33 |
| Medroxyprogesterone Acetate | 12 | $97 | $8 |
2015: 8 drugs
| Premarin | 40 | $8,677 | $217 |
| Vagifem | 30 | $5,440 | $181 |
| Estradiol | 35 | $2,838 | $81 |
| Vivelle-Dot | 13 | $1,630 | $125 |
| Acyclovir | 11 | $1,267 | $115 |
| Progesterone | 29 | $983 | $34 |
| Medroxyprogesterone Acetate | 11 | $80 | $7 |
| Lorazepam | 15 | $37 | $2 |
2014: 7 drugs
| Premarin | 26 | $5,888 | $226 |
| Vivelle-Dot | 43 | $4,946 | $115 |
| Vagifem | 30 | $3,814 | $127 |
| Prometrium | 12 | $1,595 | $133 |
| Progesterone | 24 | $1,474 | $61 |
| Estradiol | 17 | $534 | $31 |
| Medroxyprogesterone Acetate | 15 | $197 | $13 |
2013: 6 drugs
| Premarin | 37 | $7,262 | $196 |
| Vivelle-Dot | 46 | $4,495 | $98 |
| Vagifem | 34 | $3,489 | $103 |
| Progesterone | 31 | $2,432 | $78 |
| Estradiol | 33 | $409 | $12 |
| Medroxyprogesterone Acetate | 11 | $113 | $10 |
Money from drug and device companies
$68 in 2025
| 2025 | 2 | 3 | None | $68 |
| 2024 | 2 | 2 | None | $185 |
| 2020 | 4 | 7 | None | $127 |
| 2019 | 9 | 29 | None | $525 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Thinprep 2000 Processor | $46 | 2 payments
|
| Merck Sharp & Dohme | Gardasil 9 | $22 | 1 payment
|
See all 3 published payments
| Merck Sharp & Dohme | Meals · 2025-11-18 | Gardasil 9 | $22 |
| Hologic Sales and Service | Meals · 2025-10-02 | Thinprep 2000 Processor | $25 |
| Hologic Sales and Service | Meals · 2025-09-15 | Aptima | $21 |
See earlier years (2024, 2020, 2019)
2024: $185
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $165 | 1 payment
|
| Astellas Pharma US | Veozah | $21 | 1 payment
|
2020: $127
| AbbVie | Orilissa | $57 | 3 payments
|
| Avion Pharmaceuticals | Balcoltra | $32 | 2 payments
|
| Allergan | Lo Loestrin Fe | $22 | 1 payment
|
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
2019: $525
| AbbVie | Orilissa | $143 | 9 payments
|
| TherapeuticsMD | Imvexxy | $116 | 7 payments
|
| Avion Pharmaceuticals | Prenate Mini | $95 | 5 payments
|
| Hologic | Aptima Combo 2 | $51 | 2 payments
|
| Coloplast | Altis | $38 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $27 | 2 payments
|
| Sanofi Pasteur | Fluzone High-Dose | $21 | 1 payment
|
| Vertical Pharmaceuticals | Relexxii | $18 | 1 payment
|
| Merck Sharp & Dohme | Nuvaring | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407956527
- Licence
- CA G50676California G50676: Current · expires 2028-08-31
- Trained
- University of Southern California Keck School of Medicine, 1977 · 49 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 637 Lucas Ave, Suite 200, Los Angeles, CA, 90017
- NPI first listed
- 2006-09-25
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.